

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number  
WO 01/09363 A1

(51) International Patent Classification<sup>7</sup>: C12N 15/90, 15/10, 9/22

(21) International Application Number: PCT/US00/21052

(22) International Filing Date: 2 August 2000 (02.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/146,686 2 August 1999 (02.08.1999) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: REZNIKOFF, William, S.; 733 Lakewood Boulevard, Madison, WI 53704 (US). NAUMANN, Todd, A.; 608 Eagle Heights, Apt. D, Madison, WI 53705 (US).

(74) Agent: BERSON, Bennett, J.; Quarles & Brady LLP, P.O. Box 2113, Madison, WI 53701-2113 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FL, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUTANT TNS TRANSPOSSASE ENZYMES AND METHOD FOR THEIR USE



(57) Abstract: Modified Tn5 transposase proteins having a preference for transposon Tn5 inside ends rather than outside ends are disclosed and can be used in combination with transposase enzymes that prefer outside ends to inside ends in a method for end-specific directed transposition *in vivo* or *in vitro*.

WO 01/09363 A1

**THIS PAGE BLANK (USPTO)**

## MUTANT TNS TRANSPOSE ENZYMES AND METHOD FOR THEIR USE

## CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of US provisional patent application number 60/146,686, filed on August 2, 1999, which is incorporated herein by reference in its 5 entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH  
OR DEVELOPMENT

This invention was made with United States government support awarded by the following agency: NIH, Grant No. GM50692. The United States government has 10 certain rights in this invention.

## BACKGROUND OF THE INVENTION

Bacterial transposons such as Tn5 evolved within the cell by maintaining a low mobility level. While necessary for the transposon to survive, the low mobility level has inhibited the ability of researchers to detail the molecular transposition process and to 15 exploit the transposition process for use, e.g., in the development of new diagnostic and therapeutic resources. Tn5 is a conservative "cut and paste" transposon of the IS4 family (Rezsoszazy,R., Hallet,B., Delcour,J., and Mahillon,J, "The IS4 family of insertion sequences: evidence for a conserved transposase motif," Mol Microbiol. 9:1283-1295 (1993)) that encodes a 53kD transposase protein (Tnp) that is responsible 20 for its movement. The wild-type Tn5 transposase amino acid and nucleic acid sequences are known. Ahmed, A. and Podemski, L. The Revised Sequence of Tn5. Gene 154(1),129-130(1995), incorporated by reference as if set forth herein in its 25 entirety. A nucleic acid sequence that encodes wild-type Tn5 transposase is attached as SEQ ID NO:1. A polypeptide sequence encoded by SEQ ID NO:1 which corresponds to wild-type Tn5 transposase is attached as SEQ ID NO:2.

The Tnp protein facilitates movement of the entire element by binding initially to each of two 19bp specific binding sequences termed outside end (OE; SEQ ID NO:3), followed by formation of a nucleoprotein structure termed a synapse, blunt ended cleavage of each end, association with a target DNA, and then strand transfer 30 (Reznikoff,W.S., Bhasin,A., Davies,D.R., Goryshin,I.Y., Mahnke,L.A., Naumann,T., Rayment,I., Steiniger-White,M., and Twining,S.S., "Tn5: A molecular window on

transposition," *Biochem. Biophys. Res. Commun.* 266:729-34 (1999)). Tn5 transposase can also promote movement of a single insertion sequence by using a combination of OE and inside end (IE; SEQ ID NO:4) sequences. The IE is also 19bp long and is identical to OE at 12 of 19 positions (Fig. 1). *In vivo*, Tn5 transposase 5 exhibits a marked preference for OE in *E. coli*. Transposase recognition and binding to IE is inhibited in *E. coli* by the presence of two dam methylation sites (GATC palindromes) which add four methyl groups per inside end sequence (IE<sup>ME</sup>; also depicted as SEQ ID NO:4, methylation not shown) (Yin,J.C.P., Krebs,M.P., and Reznikoff,W.S., "Effect of dam Methylation on Tn5 Transposition," *J. Mol Biol.*, 199:35-45 (1988), 10 incorporated by reference as if set forth herein in its entirety). This methylation reduces transposition by reducing protein-DNA primary recognition (Jilk, R.A., York,D., and Reznikoff, W.S., "The organization of the outside end of transposon Tn5," *J. Bacteriol.* 178:1671-1679 (1996)).

A principal roadblock to understanding how Tn5 transposes is the fact that 15 purified wild-type Tnp has no detectable activity in vitro. Recently, a double mutant hyperactive form of transposase ("Tnp EK/LP") that promotes all steps of the transposition reaction *in vitro* was developed. The Tnp EK/LP protein differs from wild-type Tn5 Tnp at position 54 (Glu to Lys mutation) and at position 372 (Leu to Pro mutation), in addition to a non-essential but advantageous change at position 56 that 20 prevents production of a so-called inhibitor protein. The modified hyperactive Tnp protein retains the dramatic preference for OE (or OE-like) termini of wild-type Tn5 transposase. Tnp EK/LP has clarified many aspects of Tn5 transposition that were not previously adequately addressable *in vivo*.

*In vitro* polynucleotide transposition is a powerful tool for introducing random or 25 targeted mutations into a genome. Useful *in vitro* transposition systems based upon the Tn5 transposon are disclosed in US Patent No. 5,925,545 and International Publication No. WO 00/17343, both of which are incorporated herein by reference in their entirety as if set forth herein.

A Tnp protein having an ability to discriminate between IE and OE and having a 30 preference for binding IE is desired to permit directed nucleic acid transposition and to facilitate more complex transposition and genetic engineering strategies of the type disclosed in the above-mentioned patent and application than are available using a Tnp having a single specificity for OE. A Tnp having an enhanced preference for IE<sup>ME</sup> is also desired because methylation of DNA in common dam+ bacterial hosts inhibits 35 binding of existing Tn5 transposases and reduces the ability of existing transposases to facilitate movement of IE-defined transposons.

## BRIEF SUMMARY OF THE INVENTION

The present invention is summarized in that a transposase protein modified relative to wild-type Tn5 Tnp as disclosed herein preferentially promotes transposition of a target sequence flanked with wild-type Tn5 transposon inside ends (IE) rather than 5 outside ends (OE) without regard to whether the IE sequences are methylated.

In a related aspect, the present invention is also summarized in that a transposase modified relative to wild-type Tn5 Tnp as disclosed herein has a preference for IE over OE and is hyperactive with regard to transposition frequency.

10 In another related aspect, the present invention is also summarized in that a transposase modified relative to wild-type Tn5 Tnp as disclosed herein has a preference for IE over OE and catalyzes transposition at a high level even when the IE sequences are methylated. In contrast, wild-type Tn5 transposase does not efficiently recognize methylated IE sequences.

15 In yet another related aspect, the present invention is summarized in that a transposase according to the invention includes a mutation relative to wild type Tn5 transposase that either (1) alters binding of the transposase to the DNA termini or (2) enhances transposition or (3) both. The mutation can be end-sequence-specific (as in the exemplified embodiments that alter DNA binding) or non-specific (as in the exemplified embodiment that enhances transposition).

20 In still another related aspect, the present invention is summarized in that a transposase according to the invention has (1) a greater preference for IE than OE and (2) differs from wild-type Tnp in at least one an amino acid selected from the group consisting of amino acid 58, amino acid 344 and amino acid 372.

25 In still another related aspect, the present invention is summarized in that a transposase according to the invention differs from wild-type Tnp in that it contains at least one of a mutation from glutamic acid to valine at amino acid 58, a mutation from glutamic acid to lysine at amino acid 344, and a mutation from leucine to glutamic acid at amino acid 372.

30 In another related aspect the invention is summarized in that the transposase of the invention can also exhibit a greater preference for IE by reducing the preference for OE. A mutation at amino acid position 8 relative to wild-type transposase can reduce the preference of a transposase for OE, and thereby increase the apparent preference for IE. A mutation from arginine to cysteine can accomplish this modification.

35 A transposase protein of the invention can promote more transposition of an IE-flanked target sequence *in vivo* or *in vitro* than wild-type Tn5 transposase does. A suitable method for determining transposase enzyme activity *in vitro* is disclosed herein and in US Patent No. 5,925,545, incorporated herein by reference in its entirety. A

suitable method for determining transposase activity *in vivo* is disclosed herein.

The modified Tn5 Tnp of the present invention differs from wild-type Tn5 Tnp by virtue of at least one a change to an amino acid position, where the change is selected from the group consisting of (1) a change at amino acid position 58 that reduces or 5 eliminates a negative interaction between the Tnp and a methylated DNA residue and (2) a change at amino acid position 344 that alters DNA binding. In addition to the changes noted herein, the modified Tnp's of the invention can also include a change at position 56 (such as a Met to Ala change) that prevents production of the so-called inhibitor protein that interferes with transposition. Moreover, the mutant Tn5 10 transposase proteins can contain mutations in addition to those noted above. Additional mutations relative to the wild-type Tn5 Tnp are disclosed below. The effect of each mutation is disclosed below and it is understood that the applicants have identified amino acid residues of the protein that have a direct impact upon function and that other modifications at the same positions can have effects comparable to, greater than or 15 lesser than those noted on the preference of the protein for inside ends. The wild-type Tn5 transposase amino acid sequence is presented in the Sequence Listing. Exemplified changes relative to that wild-type transposase are presented in the text of this application.

The invention is further summarized in that the enzymes disclosed herein 20 facilitate a simple, *in vitro* system and method for introducing any transposable element from a donor DNA into a target DNA when the transposable element DNA is flanked on either side by IE termini inverted relative to one another. Few other requirements on either the donor DNA or the target DNA are envisioned. It is thought that Tn5 has few, if any, preferences for insertion sites, so it is possible to use the system to introduce 25 desired sequences at random into target DNA. Therefore, it is believed that this system and method, employing the modified transposase described herein and a simple donor DNA, is broadly applicable to introduce changes into any target DNA, without regard to its nucleotide sequence. It will, thus, be applied to many problems of interest to those skilled in the art of molecular biology.

Finally, although the changes noted herein are disclosed in terms of changes at 30 the protein level, it is well within the ability of a skilled artisan to modify a polynucleotide that encodes a Tn5 transposase protein to encode the modified proteins of the invention. The skilled artisan also understands the degeneracy of the genetic code and understands that a plurality of codons can direct the production of a single amino 35 acid residue.

The invention will be more fully understood upon consideration of the following detailed description taken in conjunction with the accompanying drawings.

## BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Fig. 1 depicts the structure of Tn5 transposase and the nucleotide sequences of Tn5 outside ends (OE), inside ends (IE), methylated inside ends (IE<sup>ME</sup>), and modified IE (IE12A).

5 Fig. 2 is a schematic depiction of the molecular basis for a papillation assay for observing transposition *in vivo*.

Fig. 3A depicts the locations of mutations observed in four successive rounds (A, B, C, D) of mutagenesis/recombination. Fig. 3B depicts the *in vivo* transposition profile of each of the mutants of Fig. 3A.

10 Fig. 4 depicts the relative preference of mutant transposases obtained in successive rounds of mutagenesis/recombination for OE and IE in a dam- strain of *E. coli*.

Fig. 5A depicts a plasmid suitable for use in an *in vitro* transposition method. Fig. 5B depicts the transposition products obtained using a mutant transposase of the 15 invention to catalyze transposition *in vitro*. Fig. 5C further characterizes the products of lane 2 of Fig. 5B.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Random mutagenesis studies performed on the Tnp gene have demonstrated that it is possible to isolate mutations in the protein that increase the rate of transposition 20 (Krebs and Reznikoff, 1988; DeLong, A., and Syvanen, M., "Trans-acting transposase mutant from Tn5," P.N.A.S. U.S.A. 88:6072-6 (1991); Wiegand, T.W., and Reznikoff, W.S., "Characterization of two hypertransposing Tn5 mutants," J. Bacteriol. 174:1229-1239 (1992); Weinreich, M.D., Gasch, A., & Reznikoff, W.S., "Evidence that the cis preference of the Tn5 transposase is caused by nonproductive multimerization," 25 Genes. Dev. 8: 2363-2374 (1994); Zhou, M., & Reznikoff, W.S., "Tn5 mutants that alter DNA binding specificity," J. Mol. Biol. 271:362-73. (1997), incorporated by reference as if set forth herein in its entirety). This makes transposase unique in comparison to most enzymatic proteins that appear to have evolved for maximum *in vivo* activity. This is likely due to the fact that high rates of transposition would be detrimental to the 30 survival of the transposon and hence transposase has evolved to have an 'optimal' level that is much lower than its maximum attainable level.

Applicants have isolated a set of related mutant transposase proteins that differ from wild type Tn5 transposase in that the mutant proteins show a preference in a transposition system for inside ends (IE), and in some cases, methylated inside ends 35 (IE<sup>ME</sup>), rather than for outside ends (OE), which are unmethylated because they lack a methylation site. The end preference of a mutant transposase can be characterized either

(1) by the *in vivo* transposition frequency observed when it is used in a system in which the target polynucleotide is flanked with either OE and IE<sup>ME</sup> termini, or (2) by the ratio of the *in vivo* transposition frequencies observed when it is used in a pair of systems in which the target polynucleotide is flanked with OE and IE<sup>ME</sup> termini, respectively.

5 Although applicants have exemplified a number of transposase proteins differing from wild-type Tn5 Tnp at one, four, five, and seven mutations, one can reasonably predict from their analysis the effects of particular individual mutations.

## EXAMPLE

### Overview

10 A number of related methods were used to obtain the family of mutants disclosed herein. In a first method, the applicants obtained mutants that restored *in vivo* transposition activity to a mutated end binding sequence that is not recognized as a substrate by wild type transposase. In a second method, the applicants introduced directed mutations into certain products of the first method to determine the preferred 15 structure of a mutant transposase according to the invention.

In the first method, the mutant IE end binding sequence contains an adenine in place of thymine at position 12 ("IE12A"; SEQ ID NO:5). The thymine-to-adenine change in IE12A destroys one of the two methylation sites of wild-type IE. Applicants used sPCR, a combinatorial, random directed mutagenesis technique to obtain modified 20 transposase proteins that can restore transposition activity to polynucleotides flanked with IE12A. sPCR was developed and described Stemmer, W.P., "Rapid evolution of a protein in vitro by DNA shuffling," *Nature* 370:389-391 (1994) and Stemmer, W.P., "DNA shuffling by random fragmentation and reassembly: in vitro recombination for 25 molecular evolution," *Proc. Natl. Acad. Sci. U.S.A.* 91:10747-10751 (1994), both of which are incorporated by reference herein as if set forth in their entirety. Briefly, DNA 30 is manipulated in vitro in the sPCR method to introduce point mutations and to allow random recombination within a population of mutant sequences. The mutated genes can be cloned into plasmids which can be selected for increased activity *in vivo*. Clones having desirable phenotypes are then used as substrates for subsequent rounds of mutagenesis/recombination and selection for a further improved phenotype.

The sPCR method can be used in conjunction with a screen (instead of a selection) in which a modest number of colonies ( $\sim 10^4$ ) are analyzed per round (Crameri, A., Whitehorn, E.A., and Stemmer, W.P., "Improved green fluorescent protein by molecular evolution using DNA shuffling," *Nat. Biotechnol.* 14:315-319 (1996), and 35 Zhang, J.H., Dawes, G., and Stemmer, W.P., "Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening," *Proc. Natl. Acad. Sci. U.S.A.* 94,

4504-4509 (1997), both of which are incorporated by reference herein as if set forth in their entirety. A papillation assay described in the Example that follows was used as a screen for transposase mutants that restore transposition activity to polynucleotides flanked with IE12A. The papillation assay is a modification of the assay described by

5       Krebs, M.P., and Reznikoff, W.S., "Use of a Tn5 derivative that creates lacZ translational fusions to obtain a transposition mutant," *Gene* 63:277-85 (1988), incorporated by reference in its entirety as if set forth herein. In the papillation assay, productive transposition in frame into an actively expressed gene results in formation of a  $\beta$ -Gal fusion protein. These cells turn blue (due to presence of X-gal) and grow at an 10 increased rate within the colony (lactose utilization). The rate at which these papillae form can be used to compare transposition rates promoted by mutated proteins.

The applicants determined the ability of mutant transposases identified using the first method to catalyze *in vivo* transposition of polynucleotides flanked either with wild-type OE or with wild-type IE in a *dam*- strain (i.e., the nucleic acid was unmethylated).

15      Among the mutants identified using the method, applicants identified a mutant transposase ("Tnp sC7") that retained near-wild-type activity with OE-flanked polynucleotides but which had very high activity with IE-flanked polynucleotides and even higher activity with IE-flanked polynucleotides when tested in a *dam*+ strain (i.e., the nucleic acid was methylated, subsequently "IE<sup>ME</sup>"). Tnp sC7 contains seven 20 mutations relative to wild-type transposase.

In the second method, it was subsequently determined that a related mutant transposase ("Tnp sC7v2.0") having only four of the seven mutations of Tnp sC7 exhibited a still higher IE<sup>ME</sup>:OE activity ratio. Both Tnp sC7 and Tnp sC7v2.0 contain a mutation that inhibits OE related activity (R8C), two mutations that specifically increase 25 IE<sup>ME</sup> related activity (E58V, E344K), and a mutation that increases transposition of polynucleotides flanked by either IE<sup>ME</sup> or OE (L372Q).

#### Obtaining the mutant Tnp's

The modified papillation assay used to screen for productive transposition is shown and described in Fig. 2. In a first plasmid ("pRZ9904 (IE12A/IE12A)") used, a 30 pair of inverted IE12A termini flank a polynucleotide that contains a lacZ gene but which lacks both a promoter and a translational start site. A second plasmid ("pRZ9905") used in the assay, encodes for transposase that can move the lacZ-containing polynucleotide. Plasmids having these attributes can readily be constructed by a skilled artisan. Materials and methods are detailed below.

35      Five random mutants that suppressed the end sequence mutation and yielded papillae after an initial cycle of mutagenesis/recombination. Equal amounts of plasmid

encoding each of these mutant transposases were then used as the initial substrates for a second round of mutagenesis/recombination. Following this second round, the mutated transposase genes were cloned into vector DNA and screened a second time for transposition activity with IE12A-defined polynucleotides via the papillation screen.

5 From this second round, a total of 6 active mutants were isolated. A third round of mutagenesis/recombination was then performed followed by screening for activity with the mutant end sequence. This time hundreds of colonies were positive for papillation. Of these, 7 were clearly more active than the others and were isolated to serve as a template for a fourth round. In the fourth round of screening there were hundreds of  
10 transposing colonies visualized during the screening process. None of these, however, were as active as the most active mutant from the third round of mutagenesis/recombination (Tnp sC6).

The most active isolate from each round was sequenced and tested for transposition activity with IE12A defined transposons in a quantitative papillation assay  
15 (see Figs. 3A and 3B). Fig. 3A depicts the mutations relative to wild-type Tnp of Tnp sA5 (best first round papillator), sB2 (best second round papillator), sC6 (best third round papillator), and sD5 (best fourth round papillator). Fig. 3B depicts the transposition activities of the four isolates *in vivo* in the papillation assay. Tnp WT was also tested but failed to promote a single detectable transposition event. The mutation  
20 Q81H is the only mutation that distinguishes the most active mutant, sC6, isolated in the third round, from the noticeably less active mutant sB2, isolated in the second round. A second isolate from the third round, Tnp sC7, is similar to the fourth round isolate sD5, except that it has two additional mutations (D217A and E344K). Tnp sC7's activity with IE12A defined transposons is similar to that of the fourth round isolate sD5 (data not  
25 shown).

The mutant Tnp's can promote transposition of OE- and IE-defined transposons

The mutant Tnp's described above were of initial interest because they could restore transposition activity to transposons flanked with IE12A termini that are inactive in the presence of wild-type Tnp. Although the transposase mutants functioned  
30 increasingly well with these transposons, the transposition rate did not approach the level of activity that is required *in vitro*. In fact, the *in vivo* activity of Tnp sC6 with IE12A ends only restored activity to a level similar to that of Tnp WT with transposons defined by OE (data not shown).

Interestingly, however, most of the isolated mutants were hyperactive with  
35 transposons defined by at least one of the native end sequences (IE or OE). These transposition preferences were determined in a dam- (DNA unmethylated) strain using

the mating out assay of Goryshin, I. Y., Kil, Y. V., and Reznikoff, W. S., "DNA length, and twisting constraints on IS50 transposition," Proc Natl Acad Sci U S A 91:10834-10838 (1994), incorporated by reference as if set forth herein in its entirety.

Fig. 4 depicts the in vivo transposition activity of 25 mutant Tnps with IE and OE defined transposons in the mating-out assay in a dam- strain, normalized to the activity of wild-type Tnp ( $6.5 \times 10^{-5}$  normalized to 1). In this assay in a dam- environment, Tnp WT shows generally equivalent activity levels whether the substrate polynucleotide is flanked with IE or with OE. On the other hand, many of the mutants exhibited higher activity with IE than with OE. This is not surprising, since the mutants were obtained in a screen using IE12A, which differs from IE at only 1 nucleotide. In contrast, OE differs from IE12A at 6 nucleotides. One mutant in particular, Tnp sC7, displayed a very interesting phenotype. It is markedly hyperactive with IE transposons while exhibiting little change in the frequency of OE transposon movement. The ability to discriminate between IE and OE is important because it facilitates multi-part transpositions that separately employ IE and OE ends, where a reaction can be directed one way or another by providing a transposase that prefers either IE or OE. A preference for IE over OE of greater than about 5-fold may be suitable, though a preference of greater than about 10-fold for IE is more preferred. A preference of greater than about 20-fold is still more preferred. Fig. 4 demonstrates that a skilled artisan can obtain such mutant transposases using the methods disclosed herein. In particular, mutants sB1, sC6, sC7, sD1 and sD3 are examples of such mutants.

Even more significantly, however, Tnp sC7 is not only not inhibited for transposition activity by methylated IE (which reduces Tnp WT levels by ~102) but actually prefers IE<sup>ME</sup> transposons to those flanked by IE, as is shown in the mating out results of Table 1 which indicate that transposition frequency with OE is reduced in a dam+ strain for both Tnp sC7 and Tnp WT. Since binding of Tnp to OE is not affected by dam methylation, this difference merely reflects the difference in transposition activity between dam+ strains and dam- strains. Despite this reduction, the rate of IE defined transposition facilitated by Tnp sC7 is even higher in the dam+ strain due to the presence of methylation in the ends. In contrast, methylation of the end sequence inhibits recognition by wild-type transposase. On the basis of its ability to discriminate between IE and OE, and because of its insensitivity to methylation of IE, subsequent attention was directed to Tnp sC7.

Table 1. *In vivo* transposition rate of Tnp WT and Tnp sC7.

	JCM101 (dam-)			RZ212 (dam+)		
	IE freq.	OE freq.	IE/OE	IE <sup>ME</sup> freq.	OE freq.	IE <sup>ME</sup> /OE
Tnp WT	6.5X10 <sup>-5</sup>	6.5X10 <sup>-5</sup>	1.0	1.0X10 <sup>-8</sup>	3.1X10 <sup>-6</sup>	3.2X10 <sup>-3</sup>
5 Tnp sC7	1.8X10 <sup>-3</sup>	3.7X10 <sup>-5</sup>	50	2.6X10 <sup>-3</sup>	3.3X10 <sup>-6</sup>	794

The role of the individual Tnp sC7 mutations in transposition activity

To understand how individual mutations affect the activity of the protein and in an effort to maximize the activity of the protein and its ability to discriminate between IE<sup>ME</sup> and OE, the applicants strategically prepared more variant transposases using 10 information obtained from sC7, which as noted above, contained seven mutations relative to wild type transposase. Since a comprehensive trial of all possible combinations of these seven mutations was cumbersome (128 possible combinations) two classes of seven mutants each were engineered. In each mutant of the first class, a unique mutation from sC7 was engineered to revert to wild-type at that position. This 15 set of so-called "minus one" mutant transposases included all possible mutants having 6 of the 7 mutations. In each mutant of the second class, wild-type transposase was engineered to contain exactly one of the 7 mutations from sC7. The set of so-called "plus one" mutant transposases included all possible mutants having only 1 of the 7 mutations. These mutant proteins were all assayed for in vivo transposition activity with 20 IE<sup>ME</sup> and OE by mating out assays. The results of the analysis are shown in Table 2.

Table 2. Results of 'minus ones/plus ones' analysis.

		'minus one' IE <sup>ME</sup>		'minus one' OE		'plus one' IE <sup>ME</sup>		'plus one' OE	
		freq.	norm.	freq.	norm.	freq.	norm.	freq.	norm.
<b>Wild-type</b>									
						1.0X10 <sup>-8</sup>	1.0	3.1X10 <sup>-6</sup>	1.0
5	sC7	2.6X10 <sup>-3</sup>	1.0	3.3X10 <sup>-5</sup>	1.0				
	RC8C	3.1X10 <sup>-3</sup>	1.2	6.0X10 <sup>-6</sup>	1.8	-----	---	4.0X10 <sup>-7</sup>	0.1
	E58V	1.8X10 <sup>-6</sup>	6.9X10 <sup>-4</sup>	1.1X10 <sup>-6</sup>	0.3	4.0X10 <sup>-4</sup>	4X10 <sup>4</sup>	1.4X10 <sup>-6</sup>	0.5
	A157T	3.1X10 <sup>-3</sup>	1.2	4X10 <sup>-6</sup>	1.2	-----	---	6.6X10 <sup>-7</sup>	0.2
	T171S	2.8X10 <sup>-3</sup>	1.1	2.6X10 <sup>-6</sup>	0.8	5.6X10 <sup>-9</sup>	0.6	1.8X10 <sup>-6</sup>	0.6
10	D217A	3.7X10 <sup>-3</sup>	1.3	4.5X10 <sup>-6</sup>	1.4	-----	---	3.4X10 <sup>-6</sup>	1.1
	E344K	5.5X10 <sup>-4</sup>	0.2	1.7X10 <sup>-5</sup>	5.2	4.3X10 <sup>-8</sup>	4.3	6.8X10 <sup>-7</sup>	0.2
	L372Q	2.6X10 <sup>-4</sup>	0.1	2.8X10 <sup>-7</sup>	0.1	8.9X10 <sup>-8</sup>	8.9	1.1X10 <sup>-5</sup>	3.5

a. 'Minus ones' contain all mutations present in Tnp sC7 except at indicated position. e.g. R8C 'minus one' contains the wild-type argenine at position 8.

15 b. 'Plus ones' are Tnp WT except that the indicated amino acid is mutated to the residue present in Tnp sC7. E.g. R8C 'plus one' contains a cysteine at amino acid 8.

Sequence-specific mutations. The mutation E58V has the most profound effect of all the mutations on the activity of Tnp sC7. This mutation in the wild-type background (E58V 'plus one') increases IE<sup>ME</sup> related transposition by 40,000 fold while removal of the mutation from Tnp sC7 (E58V 'minus one') drops the total activity by more than 1,000 fold. The mutation has comparatively little effect on OE related activity.

The mutation E344K exhibits a similar, though much weaker, sequence specific effect on activity. When removed from Tnp sC7 (E344K 'minus one'), IE<sup>ME</sup> related activity decreases by 5 fold while OE related activity is stimulated about 5 fold. This result is mirrored in the 'plus ones' data as E344K in the wild type background stimulates IE<sup>ME</sup> related activity 4 fold and decreases OE related activity about 5 fold.

Non-sequence-specific mutations. The mutation L372Q strongly stimulates Tnp sC7 activity with IE<sup>ME</sup>. When removed from sC7 both IE<sup>ME</sup> and OE related activity are reduced to the same degree. When added to wild-type transposase, its 'plus one' phenotype stimulates activity with both substrates.

Other mutations. The mutation R8C was the most interesting of the remaining four mutations. When the mutation is added to wild-type transposase, OE related

transposition was reduced nearly 10 fold. When the mutation was removed from sC7 OE related activity increased approximately 2 fold. In a methylating host, its removal from sC7 had little effect on IE<sup>ME</sup> related activity while by itself it decreased IE<sup>ME</sup> related activity to below detectable levels. None of the remaining three (A157T, T171S, 5 D217A) mutations has much effect on either IE<sup>ME</sup> or OE related activity when removed from sC7. To determine whether any combination of these mutations would lead to an increase in overall IE<sup>ME</sup> related activity without sacrificing its specificity for IE<sup>ME</sup> over 10 OE, the applicants engineered pairwise reversions of sC7 at these positions as well as a triple-reversion mutant. The construct with all three of these mutations reverted had the second highest IE<sup>ME</sup> related activity and the best ability to discriminate between IE<sup>ME</sup> and OE (Table 3). This four-mutant construct, Tnp (R8C, E58V, E344K, L372Q), was renamed Tnp sC7 v2.0.

Table 3. *In vivo* frequency of Tnp sC7 with indicated mutations reverted to wild type. Numbers in parenthesis indicate positions changed to wild-type.

15		IE <sup>ME</sup>		OE		IE <sup>ME</sup> /OE
		freq.	norm.	freq.	norm.	
	Tnp sC7	2.6X10 <sup>-3</sup>	1.0	3.3X10 <sup>-6</sup>	1.0	794
	Tnp sC7(157,171)	6.5X10 <sup>-3</sup>	2.5	7.0X10 <sup>-6</sup>	2.1	933
	Tnp sC7(157,217)	8.4X10 <sup>-3</sup>	3.3	2.25X10 <sup>-5</sup>	6.8	373
20	Tnp sC7(171,217)	5.8X10 <sup>-3</sup>	2.3	1.18X10 <sup>-5</sup>	3.6	502
	Tnp sC7(157,171,217)α	7.4X10 <sup>-3</sup>	2.8	7.1X10 <sup>-6</sup>	2.1	1042

α Re-named sC7v2.0.

Abbreviations: OE = outside end

IE = inside end

25 IE<sup>ME</sup> = dam methylated inside end

Tnp sC7 is less than the sum of its individual mutations. The Tnp E58V (E58V 'plus one') mutant has an activity increase of 4X10<sup>4</sup> over Tnp WT alone. The composite mutant with E58V removed (E58V 'minus one') has an increase of 1.8X10<sup>2</sup> over Tnp WT. Additivity would then predict that Tnp sC7 would have an activity increase of:

30  $(4 \times 10^4)(1.8 \times 10^2) = 7.2 \times 10^6$

However the stimulation of the composite mutation is actually much lower ( $2 \times 10^5$ ). In other words the increase obtained by adding E58V to the other 6 mutations is  $1.1 \times 10^3$  fold, and not the  $4 \times 10^4$  fold stimulation seen by adding E58V into the wild-type background. This may be because that E58V and E344K are both stimulating the same 5 step (primary DNA binding) and are less than additive when combined.

Tnp sC7v2.0 effectively transposes IE<sup>ME</sup> defined transposons in vitro

The ability of Tnp sC7v2.0 to promote transposition of IE<sup>ME</sup> defined transposons in vitro was tested under the same conditions developed for movement of OE defined transposons by Tnp EK/LP (Goryshin, I.Y., and Reznikoff, W.S., "Tn5 in vitro 10 transposition," *J. Biol. Chem.* 273:7367-7374 (1998), incorporated by reference as if set forth herein in its entirety). Substrate plasmid pGT4, a high-copy number pUC19-based vector in which inverted IE<sup>ME</sup> end sequences flank a kanamycin resistance gene, was purified as a supercoiled monomer (see Materials and Methods). This plasmid was 15 constructed so that digestion with Pvull restriction endonuclease causes release of the transposon from the donor backbone DNA (see Fig. 5A). Tnp sC7v2.0 was produced and purified by cloning the nucleotide sequence in an expression vector, expressing the protein in a host cell and isolating the protein from an extract from the host cell, all using 20 standard methods known to a skilled artisan.

Incubation with Tnp sC7v2.0 results in conversion of 66% of supercoiled 25 plasmid into transposition products and intermediates after a three hour incubation. In Fig. 5B, lane 1 is unreacted substrate pGT4. The transposition activity promoted by Tnp sC7v2.0 on IE<sup>ME</sup> transposons is shown in lane 2 Lane 3 is the result of pGT4 digestion with Pvull restriction endonuclease.

Though transposition reactions performed in this fashion can lead to many 30 different DNA products, the reaction can be interpreted by analyzing certain diagnostic fragments as defined previously by Goryshin and Reznikoff (1998), *supra*. Fig. 5C is a reproduction of lane 2 of Fig. 5B. Band 1 is the excised transposon. It is an intermediate that has undergone double ended break from the plasmid but has not undergone strand transfer. Band 2 is the donor backbone DNA that is released upon double-ended 35 excision of the transposon. These bands have the same molecular weight as the products of the Pvull digest shown in lane 3 of Fig. 5B. Band 3 represents substrate plasmid that has undergone cleavage at one transposon end. It migrates at the same position as linearized plasmid (data not shown). Bands 4 and 5 are two different types of strand transfer products. Band 4 is the result of a transposon inserting intermolecularly into an unreacted plasmid. This results in a relaxed circular DNA that is longer than the original 40 substrate plasmid by the length of the inserted transposon. The bands denoted as 5 are

the result of intramolecular inversion events. These transposition products are the size of the transposon but circularized. These circularized transposition products can contain differing numbers of nodes and hence migrate in different positions on the gel.

#### Structure/function analysis

5 The hyperactive Tn5 transposase mutant Tnp sC7v2.0, which increases transposition of IE<sup>ME</sup> flanked transposons by 7.4X10<sup>5</sup> times, includes mutations at amino acids 8, 58, 344, and 372. Analysis of Tnp sC7 revealed that the hyperactivity conferred by both the E58V and E344K mutations depends upon the transposon termini sequence. This phenotype occurring for E58V was not surprising, as previous random mutagenesis 10 screens performed with OE flanked transposons resulted in the isolation of proteins with mutations at either amino acid 47 or amino acid 54 which had sequence specific activity (Zhou and Reznikoff, 1997; Zhou,M., Bhasin,A., and Reznikoff,W.S., "Molecular genetic analysis of transposase-end DNA sequence recognition: cooperativity of three adjacent base-pairs in specific interaction with a mutant Tn5 transposase," *J. Mol. Biol.* 15 276:913-925 (1997)). The sequence specific activity of a mutation at amino acid 344 that suggests that the residue also interacts with transposon end DNA, however, was indeed very surprising.

Recently a protein-DNA co-crystal representing Tnp EK/LP complexed with pre-cut (no donor backbone) OE DNA has been solved. In this complex amino acid 58 20 is shown to interact specifically with OE at position 10. This places the mutant residue in the vicinity of position 12, the nucleotide mutation that it was initially chosen to repress. Positions 10, 11, and 12 are all different between IE and OE and furthermore it is near one of two areas that contain major groove modification by dam methylase (position 11 of top strand and position 12 of bottom strand).

25 The structure further shows that amino acid 344 interacts with DNA at position 7 of OE. While position 7 is not one of the seven that distinguishes IE from OE, it is between both position 4 and the region of nucleotides 10, 11, and 12 that differentiate the two. It is therefore plausible that the activity difference of Tnp E344K with IE and OE can be attributed to context effects of these two regions. We therefore propose that both 30 mutations E58V and E344K are interacting with end sequence DNA and alter transposase function at the level of primary sequence recognition.

The leucine to glutamine mutation (L372Q), which was present in all sequenced mutants (sA5, sB2, sC6, sC7, and sD5), was both familiar and surprising. It was familiar because a hyperactive mutation at this position was previously isolated. It was 35 surprising because the previously isolated mutation causes a leucine to proline (L372P) substitution at this position (Weinreich et al., 1994). The L372P mutation results in two

consecutive proline residues in an  $\alpha$  helix. In the co-crystal this destabilizes amino acids 372-390. It is proposed that the mutation changes the conformation of the catalytic domain in relation to the C-terminal dimerization domain. This alteration can improve activity by increasing the distance between the N and C termini. The close proximity of 5 these termini in Tnp WT is thought to decrease the rate of transposition of Tnp WT (Reznikoff et al., 1999). The wild-type leucine residue, visible in an earlier partial Tnp structure (Davies,D.R., Braam,L.M., Reznikoff,W.S. and Rayment,I., "The three-dimensional structure of a Tn5 transposase-related protein determined to 2.9-A resolution," *J Biol Chem.* 274: 11904-11913 (1999)), is buried in a hydrophobic pocket. 10 It is likely that substitution with a glutamine destabilizes this hydrophobic packaging. Given that two different hyperactive mutations have been isolated by PCR-base random mutagenesis techniques that only result in single nucleotide changes in the codon and can only make five different amino acid substitutions at this residue (methionine, valine, arginine, proline, or glutamine), it is likely that a more direct mutagenesis approach such 15 as codon randomization could reveal other interesting mutants.

The mutation R8C, which reduces OE related transposition almost 10-fold in the wild-type background (R8C 'plus one') and increases it approximately 2-fold when removed from the sC7 background (R8C 'minus one') is less easy to interpret. In the co-crystallographic structure the arginine residue is not in an area of DNA contact. 20 However this structure only represents a still picture of the complex after cleavage has occurred and it is possible that this region contacts DNA in the initial synapse.

#### IE methylation

The inside end of the Tn5 transposon contains two GATC signal sequences that add four methyl groups into the major groove of each end. In this study, we were able to 25 isolate a single mutation, E58V, which not only overcomes this binding inhibition but also appears to preferentially function on transposons in which the methyl groups are present (presumably due to increased binding affinity). Furthermore, the co-crystal structure of Tnp EK/LP complexed with pre-cleaved DNA shows that glutamate 58 interacts directly with position 10 of OE in the major groove. This region is in the 30 vicinity of the methyl group that is present on the adenine of the non-transferred strand of IE<sup>ME</sup>. The fact that a single amino acid change can result in this extreme change in phenotype leads us to propose that this methyl group alone is responsible for the inhibition of binding of transposase to IE<sup>ME</sup>. The inhibition of binding by Tnp WT to IE<sup>ME</sup> is likely caused by an interaction between this methyl group and the negatively 35 charged side chain of glutamate 58. Replacing this residue with a valine can not only remove this unfavorable interaction but also lead to an increase in binding affinity due to

hydrophobic packaging between the side chain of the valine residue and this methyl group.

### General Materials and Methods

#### Media and Reagents

5 Papillation assays were performed using glucose minimal Miller media (Miller, J., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. (1992)) supplemented with ampicillin, chloramphenicol, 5-bromo-4-chloro-3-indolyl- $\beta$ - D-galactoside, and phenyl- $\beta$ -D-galactoside (Trp--XG-PG plates) as described previously by Zhou, M., & Reznikoff, W.S., *supra*. After  
10 transformation during site directed mutagenesis, the cells were outgrown in SOC media as indicated in the altered sites protocol (Promega). All other bacterial growth was performed in Luria Broth (Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.). When necessary, antibiotics (Sigma) were added at the following  
15 concentrations: ampicillin 100 $\mu$ g/ml; chloramphenicol 20 $\mu$ g/ml; nalidixic acid 20 $\mu$ g/ml; gentamycin 5 $\mu$ g/ml; tetracycline 15 $\mu$ g/ml. Taq DNA Polymerase, T4 polymerase, T4 ligase, dNTP's, and all components of the Altered Sites Mutagenesis kit were purchased from Promega. Restriction enzymes were purchased either from Promega or New England Biolabs. Oligonucleotides used in site directed mutagenesis, sPCR, and  
20 sequencing were purchased from Research Genetics. Radionucleotides used in sequencing were from Amersham.

#### Construction of plasmids

Plasmid pGT4 was constructed as a high copy number plasmid containing a kanamycin resistance gene flanked by two inside ends. It is designed so that digestion  
25 with Pvull releases the transposon from its pUC vector backbone.

The fourteen pRZ9905 (sC7) derivatives and pRZ9905 (sC7 version 2.0) were constructed by swapping restriction fragments between pRZ9905 and pRZ9905 (sC7).

#### Bacterial Strains

Cloning of plasmids and the directed evolution process were performed in JM109  
30 (Promega). The site-directed mutagenesis protocol utilized strain ES1301 (Promega) and JM109. In the mating out assay, transposase plasmids were transformed into strain RZ212 [ $\Delta$ (lac-proA,B), ara, str, recA56, srl, thi/pOX38-Gen], followed by conjugation into 14R525[F-nalr].

Directed Evolution Process

Directed evolution of Tn5 transposase was carried out by sPCR, basically as described previously by Stemmer (1994). Forty micro liters (~4 $\mu$ g) of a pRZ9905 plasmid mini prep (Wizard SV preps, Promega) were partially digested in a 50 $\mu$ l volume containing 100mM Tris-HCl (ph = 7.0), 5nM MgCl, and 90ng of DNase I. After a 7-minute incubation at room temperature, the reactions were stopped by adding EDTA to 10mM. Following the addition of loading dye (Sambrook et. al, 1989) the digested DNA was electrophoresed in a 2% NuSieve gel (FMC BioProducts) next to pGEM DNA markers (Promega). A gel slice containing DNA fragments of 200-600bp in size as well as a second slice containing DNA fragments from 600-1000bp in size were excised from the gel. The DNA from these two slices was purified separately by phenol chloroform extraction (Sambrook et. al, 1989). After ethanol precipitation, the DNA pellets were dried and resuspended directly into 50  $\mu$ l of an assembly reaction mix. The assembly mix contained 0.2mM dNTP's; 2.0mM MgCl; 50mM KCl; 10mM Tris-HCl (pH9.0 at 25C); and 0.1% Triton X-100. After addition of 0.5 units of Taq DNA Polymerase, the DNA was reassembled by the following thermo cycling program: 94C for 30seconds; 50 cycles of 94C for 20 seconds, 65C for 1 minute, and 72C for 2 minutes; and cooling to 4C. A standard PCR amplification reaction using 5 $\mu$ l of the assembly reaction product as a DNA template was performed for each sample (200-600bp and 600-1000bp) to amplify the transposase gene. This transposase-encoding fragment was digested to completion with AflII and BglII and ligated into purified AflII/BglII digested vector DNA from pRZ9905.

Ligation products were transformed into electrocompetent JM109 cells that contained plasmid pRZ9904 (IE12A/IE12A). After outgrowth the cells were plated on Trp--XG-PG plates with chloramphenicol and ampicillin selection. The plates were incubated at 32C for 14 days. At this time pRZ9905 plasmid DNA from all colonies that exhibited at least one papillae were isolated and re-transformed into the papillation assay to confirm their papillation plus phenotype. A total of 5 pRZ9905 derivatives (out of 20,000 original colonies screened) were confirmed to be papillation plus. An equal amount of all five plasmids was then used as the substrate for a second round of mutagenesis and screening. This process was repeated for a total of four rounds of screening (~ 20,000 colonies / round)

Quantitative Papillation Assay

The IE12A in vivo transposition activity of Tnp WT, Tnp sA5, Tnp sB2, Tnp sC6, and Tnp sD5 were compared by a quantitative papillation assay. Competent cells of strain JM109 harboring plasmid pRZ9904 (IE12A/IE12A) were transformed with the

appropriate transposase-encoding version of pRZ9905. After outgrowth, transformed cells were plated on Trp--XG-PG plates with chloramphenicol and ampicillin. The plates were grown at 32C until colonies began to appear (~18 hours). Individual colonies were then picked with sterile sticks and spotted onto a fresh plate in a 4X4 grid 5 pattern to evenly space all colonies. One plate of 16 colonies was spotted for each protein. Plates were incubated at 32C and quantified for transposition by observing the appearance of papillae at 24-hour intervals. Data are expressed as the average number of papillae present per colony.

Mating out assays

10 Mating out assays were performed as described previously (Yin et al., 1988; Goryshin et al., 1994). Bacterial cells with the transposon containing plasmids pFMA52-187 (with either two OEs or two IEs) and the F factor pox-Gen were transformed with the appropriate transposase encoding plasmid pRZ9905. The donor used for the library screening was the strain JCM101 [ $\Delta$ lacZX74, raps, dam-3]. All other 15 mating out was performed in E. coli strain RZ212 [ $\Delta$ (lac-proA,B), ara, str, recA56, srl, thi]. The recipient strain used was 14R525[F-nalr]. A total of three assays were performed for each combination of transposase and end sequence. The values reported are the average of these three data points.

In vitro transposition assays

20 Substrate plasmid pGT4 was isolated from DH5 $\alpha$  cells using a qiafilter plasmid mega kit (Qiagen). Supercoiled monomer plasmid was isolated from a 1% agarose gel by use of the qiaquick gel purification kit (Qiagen). Reactions were performed at 37C under conditions determined by Reznikoff and Goryshin (1998). The concentration of pGT4 was 35.5nM. Tnp sC7v2.0 was added to a concentration of 280nM.

25 The foregoing is not intended to limit the scope of the invention. Rather the invention is understood to encompass all the variations and modifications that come within the scope of the appended claims.

## CLAIMS

## WE CLAIM:

1. A mutant Tn5 transposase protein modified relative to wild-type Tn5 transposase protein, the mutant transposase differing from the wild-type protein at a 5 position selected from the group consisting of amino acid 58 and amino acid 372, wherein the mutant Tn5 transposase protein has a preference for Tn5 inside ends over Tn5 outside ends.
2. A mutant Tn5 transposase as claimed in Claim 1 comprising a valine at amino acid position 58.
- 10 3. A mutant Tn5 transposase as claimed in Claim 1 comprising a mutation at amino acid position 372.
4. A mutant Tn5 transposase as claimed in Claim 1 comprising a glutamine at amino acid position 372.
- 15 5. A mutant Tn5 transposase as claimed in Claim 1, wherein the mutant transposase differs from the wild-type protein at amino acids 58 and 372.
6. A mutant Tn5 transposase as claimed in Claim 1 comprising a valine at amino acid position 58 and a glutamine at amino acid position 372.
7. A mutant Tn5 transposase as claimed in Claim 1 further differing from wild-type Tn5 transposase at a position selected from amino acid 8 and amino acid 344.
- 20 8. A mutant Tn5 transposase as claimed in Claim 7 wherein the amino acid at position 8 is cysteine.

9. A mutant Tn5 transposase as claimed in Claim 7 wherein the amino acid at position 344 is lysine.

10. A mutant Tn5 transposase as claimed in Claim 7 wherein the mutant Tn5 transposase differs from wild-type Tn5 transposase at amino acid position 8 and amino 5 acid position 344.

11. A mutant Tn5 transposase as claimed in Claim 1 comprising a cysteine at amino acid position 8 and a lysine at amino acid position 344.

12. A mutant Tn5 transposase as claimed in Claim 1 comprising a cysteine at amino acid position 8, a valine at amino acid position 58, a lysine at amino acid position 10 344, and a glutamine at amino acid position 372.

13. A polynucleotide that encodes a transposase as claimed in Claim 1.

14. A polynucleotide that encodes a transposase as claimed in Claim 12.

15. A system for transposing a transposable DNA sequence *in vitro*, the system comprising:

the mutant Tn5 transposase modified relative to a wild-type Tn5 transposase, as claimed in Claim 1;

a donor DNA molecule comprising the transposable DNA sequence, the sequence being flanked at its 5'- and 3' ends by a wild-type IE sequence; and

a target DNA molecule into which the transposable element can transpose.

20 16. A system as claimed in Claim 15 wherein the IE sequence is methylated.


17. A method for *in vitro* transposition, the method comprising the steps of:

combining a donor DNA molecule that comprises a transposable DNA sequence of interest, the DNA sequence of interest being flanked at its 5'- and 3'- ends by a wild-type Tn5 IE sequence, with a target DNA molecule and a mutant Tn5 transposase as


5 claimed in Claim 1 in a suitable reaction buffer at a temperature below a physiological temperature until the modified transposase binds to the IE sequences; and

raising the temperature to a physiological temperature for a period of time sufficient for the enzyme to catalyze *in vitro* transposition.

**THIS PAGE BLANK (USPTO)**

**FIG 1**

**THIS PAGE BLANK (USPTO)**

**FIG 2**

**THIS PAGE BLANK (USPTO)**





FIG 3A


**THIS PAGE BLANK (USPTO)**

## *In vivo* transposition with IE12A



**FIG 3B**




**THIS PAGE BLANK (USPTO)**



**FIG 4**

**THIS PAGE BLANK (USPTO)**

6/6

**FIG 5A****FIG 5B****FIG 5C**

**THIS PAGE BLANK (USPTO)**

## SEQUENCE LISTING

<110> Reznikoff, William S  
Naumann, Todd A

<120> Transposase Enzyme and Method for Use

5 <130> 960296.96471

<140>  
<141>

<150> 60/146686

<151> 1999-08-02

10 <160> 5

<170> PatentIn Ver. 2.1

<210> 1  
<211> 1431  
<212> DNA

15 <213> Transposon Tn5

<220>  
<221> CDS  
<222> (1)..(1428)

<400> 1

20 atg ata act tct gct ctt cat cgt gcg gcc gac tgg gct aaa tct gtg 48  
Met Ile Thr Ser Ala Leu His Arg Ala Ala Asp Trp Ala Lys Ser Val  
1 5 10 15

ttc tct tcg gcg gcg ctg ggt gat cct cgc cgt act gcc cgc ttg gtt 96  
Phe Ser Ser Ala Ala Leu Gly Asp Pro Arg Arg Thr Ala Arg Leu Val  
25 20 25 30

aac gtc gcc gcc caa ttg gca aaa tat tct ggt aaa tca ata acc atc 144  
Asn Val Ala Ala Gln Leu Ala Lys Tyr Ser Gly Lys Ser Ile Thr Ile  
35 40 45

tca tca gag ggt agt gaa gcc atg cag gaa ggc gct tac cga ttt atc 192  
30 Ser Ser Glu Gly Ser Glu Ala Met Gln Glu Gly Ala Tyr Arg Phe Ile  
50 55 60

**THIS PAGE BLANK (USPTO)**

65	70	75	80	240
Arg Asn Pro Asn Val Ser Ala Glu Ala Ile Arg Lys Ala Gly Ala Met				
5	85	90	95	288
Gln Thr Val Lys Leu Ala Gln Glu Phe Pro Glu Leu Leu Ala Ile Glu				
10	100	105	110	336
Asp Thr Thr Ser Leu Ser Tyr Arg His Gln Val Ala Glu Glu Leu Gly				
15	115	120	125	384
Lys Leu Gly Ser Ile Gln Asp Lys Ser Arg Gly Trp Trp Val His Ser				
15	130	135	140	432
Gly Ser Ile Gln Asp Lys Ser Arg Gly Trp Trp Val His Ser				
20	145	150	155	480
Gln Glu Trp Trp Met Arg Pro Asp Asp Pro Ala Asp Ala Asp Glu Lys				
25	165	170	175	528
Glu Ser Gly Lys Trp Leu Ala Ala Ala Thr Ser Arg Leu Arg Met				
30	180	185	190	576
Gly Ser Met Met Ser Asn Val Ile Ala Val Cys Asp Arg Glu Ala Asp				
25	195	200	205	624
Ile His Ala Tyr Leu Gln Asp Lys Leu Ala His Asn Glu Arg Phe Val				
30	210	215	220	672
Tyr Asp His Leu Lys Asn Gln Pro Glu Leu Gly Gly Tyr Gln Ile Ser				
225	230	235	240	720
Tyr Asp His Leu Lys Asn Gln Pro Glu Leu Gly Gly Tyr Gln Ile Ser				

**THIS PAGE BLANK (USPTO)**

att ccg caa aag ggc gtg gtg gat aaa cgc ggt aaa cgt aaa aat cga	768		
Ile Pro Gln Lys Gly Val Val Asp Lys Arg Gly Lys Arg Lys Asn Arg			
245	250	255	
cca gcc cgc aag gcg agc ttg agc ctg cgc agt ggg cgc atc acg cta	816		
5 Pro Ala Arg Lys Ala Ser Leu Ser Leu Arg Ser Gly Arg Ile Thr Leu			
260	265	270	
aaa cag ggg aat atc acg ctc aac gcg gtg ctg gcc gag gag att aac	864		
Lys Gln Gly Asn Ile Thr Leu Asn Ala Val Leu Ala Glu Glu Ile Asn			
275	280	285	
10 ccg ccc aag ggt gag acc ccg ttg aaa tgg ttg ctg acc agc gaa	912		
Pro Pro Lys Gly Glu Thr Pro Leu Lys Trp Leu Leu Leu Thr Ser Glu			
290	295	300	
ccg gtc gag tcg cta gcc caa gcc ttg cgc gtc atc gac att tat acc	960		
Pro Val Glu Ser Leu Ala Gln Ala Leu Arg Val Ile Asp Ile Tyr Thr			
15 305	310	315	320
cat cgc tgg cgg atc gag gag ttc cat aag gca tgg aaa acc gga gca	1008		
His Arg Trp Arg Ile Glu Glu Phe His Lys Ala Trp Lys Thr Gly Ala			
325	330	335	
20 gga gcc gag agg caa cgc atg gag ccg gat aat ctg gag cgg atg	1056		
Gly Ala Glu Arg Gln Arg Met Glu Glu Pro Asp Asn Leu Glu Arg Met			
340	345	350	
gtc tcg atc ctc tcg ttt gtt gcg gtc agg ctg tta cag ctc aga gaa	1104		
Val Ser Ile Leu Ser Phe Val Ala Val Arg Leu Leu Gln Leu Arg Glu			
355	360	365	
25 agc ttc acg ctg ccg caa gca ctc agg gcg caa ggg ctg cta aag gaa	1152		
Ser Phe Thr Leu Pro Gln Ala Leu Arg Ala Gln Gly Leu Leu Lys Glu			
370	375	380	
gcg gaa cac gta gaa agc cag tcc gca gaa acg gtg ctg acc ccg gat	1200		
Ala Glu His Val Glu Ser Gln Ser Ala Glu Thr Val Leu Thr Pro Asp			
30 385	390	395	400
gaa tgt cag cta ctg ggc tat ctg gac aag gga aaa cgc aag cgc aaa	1248		
Glu Cys Gln Leu Leu Gly Tyr Leu Asp Lys Gly Lys Arg Lys Arg Lys			
405	410	415	

**THIS PAGE BLANK (USPTO)**

gag aaa gca ggt agc ttg cag tgg gct tac atg gcg ata gct aga ctg 1296  
 Glu Lys Ala Gly Ser Leu Gln Trp Ala Tyr Met Ala Ile Ala Arg Leu  
 420 425 430

ggc ggt ttt atg gac agc aag cga acc gga att gcc agc tgg ggc gcc 1344  
 5 Gly Gly Phe Met Asp Ser Lys Arg Thr Gly Ile Ala Ser Trp Gly Ala  
 435 440 445

ctc tgg gaa ggt tgg gaa gcc ctg caa agt aaa ctg gat ggc ttt ctt 1392  
 Leu Trp Glu Gly Trp Glu Ala Leu Gln Ser Lys Leu Asp Gly Phe Leu  
 450 455 460

10 gcc gcc aag gat ctg atg gcg cag ggg atc aag atc tga 1431  
 Ala Ala Lys Asp Leu Met Ala Gln Gly Ile Lys Ile  
 465 470 475

<210> 2  
 <211> 476

15 <212> PRT  
 <213> Transposon Tn5

<400> 2  
 Met Ile Thr Ser Ala Leu His Arg Ala Ala Asp Trp Ala Lys Ser Val  
 1 5 10 15

20 Phe Ser Ser Ala Ala Leu Gly Asp Pro Arg Arg Thr Ala Arg Leu Val  
 20 25 30

Asn Val Ala Ala Gln Leu Ala Lys Tyr Ser Gly Lys Ser Ile Thr Ile  
 35 40 45

Ser Ser Glu Gly Ser Glu Ala Met Gln Glu Gly Ala Tyr Arg Phe Ile  
 25 50 55 60

Arg Asn Pro Asn Val Ser Ala Glu Ala Ile Arg Lys Ala Gly Ala Met  
 65 70 75 80

Gln Thr Val Lys Leu Ala Gln Glu Phe Pro Glu Leu Leu Ala Ile Glu  
 85 90 95

30 Asp Thr Thr Ser Leu Ser Tyr Arg His Gln Val Ala Glu Glu Leu Gly  
 100 105 110

**THIS PAGE BLANK (USPTO)**

Lys Leu Gly Ser Ile Gln Asp Lys Ser Arg Gly Trp Trp Val His Ser  
 115 120 125

Val Leu Leu Leu Glu Ala Thr Thr Phe Arg Thr Val Gly Leu Leu His  
 130 135 140

5 Gln Glu Trp Trp Met Arg Pro Asp Asp Pro Ala Asp Ala Asp Glu Lys  
 145 150 155 160

Glu Ser Gly Lys Trp Leu Ala Ala Ala Ala Thr Ser Arg Leu Arg Met  
 165 170 175

Gly Ser Met Met Ser Asn Val Ile Ala Val Cys Asp Arg Glu Ala Asp  
 10 180 185 190

Ile His Ala Tyr Leu Gln Asp Lys Leu Ala His Asn Glu Arg Phe Val  
 195 200 205

Val Arg Ser Lys His Pro Arg Lys Asp Val Glu Ser Gly Leu Tyr Leu  
 210 215 220

15 Tyr Asp His Leu Lys Asn Gln Pro Glu Leu Gly Gly Tyr Gln Ile Ser  
 225 230 235 240

Ile Pro Gln Lys Gly Val Val Asp Lys Arg Gly Lys Arg Lys Asn Arg  
 245 250 255

Pro Ala Arg Lys Ala Ser Leu Ser Leu Arg Ser Gly Arg Ile Thr Leu  
 20 260 265 270

Lys Gln Gly Asn Ile Thr Leu Asn Ala Val Leu Ala Glu Glu Ile Asn  
 275 280 285

Pro Pro Lys Gly Glu Thr Pro Leu Lys Trp Leu Leu Leu Thr Ser Glu  
 290 295 300

25 Pro Val Glu Ser Leu Ala Gln Ala Leu Arg Val Ile Asp Ile Tyr Thr  
 305 310 315 320

His Arg Trp Arg Ile Glu Glu Phe His Lys Ala Trp Lys Thr Gly Ala  
 325 330 335

Gly Ala Glu Arg Gln Arg Met Glu Glu Pro Asp Asn Leu Glu Arg Met  
 30 340 345 350

**THIS PAGE BLANK (USPTO)**

Val Ser Ile Leu Ser Phe Val Ala Val Arg Leu Leu Gln Leu Arg Glu  
355 360 365

Ser Phe Thr Leu Pro Gln Ala Leu Arg Ala Gln Gly Leu Leu Lys Glu  
370 375 380

5 Ala Glu His Val Glu Ser Gln Ser Ala Glu Thr Val Leu Thr Pro Asp  
385 390 395 400

Glu Cys Gln Leu Leu Gly Tyr Leu Asp Lys Gly Lys Arg Lys Arg Lys  
405 410 415

10 Glu Lys Ala Gly Ser Leu Gln Trp Ala Tyr Met Ala Ile Ala Arg Leu  
420 425 430

Gly Gly Phe Met Asp Ser Lys Arg Thr Gly Ile Ala Ser Trp Gly Ala  
435 440 445

Leu Trp Glu Gly Trp Glu Ala Leu Gln Ser Lys Leu Asp Gly Phe Leu  
450 455 460

15 Ala Ala Lys Asp Leu Met Ala Gln Gly Ile Lys Ile  
465 470 475

<210> 3

<211> 19

<212> DNA

20 <213> Transposon Tn5

<400> 3

ctgactctta tacacaagt

19

<210> 4

<211> 19

25 <212> DNA

<213> Transposon Tn5

<400> 4

ctgtctttg atcagatct

19

**THIS PAGE BLANK (USPTO)**

<210> 5  
<211> 19  
<212> DNA  
<213> Transposon Tn5

5 <400> 5  
ctgtctcttg aacagatct

19

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

Interr. Application No  
PCT/US 00/21052

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12N15/90 C12N15/10 C12N9/22

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GORYSHIN I Y ET AL: "Tn5 in vitro transposition" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 13, 27 March 1998 (1998-03-27), pages 7367-7374, XP002129603 ISSN: 0021-9258 the whole document</p> <p>----</p> <p style="text-align: center;">-/-</p>	15-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*8\* document member of the same patent family

Date of the actual completion of the international search

14 November 2000

Date of mailing of the international search report

30/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

Internatinal Application No

PCT/US 00/21052

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KREBS M P ET AL: "USE OF A TRANSPOSON TNS DERIVATIVE THAT CREATES LACZ TRANSLATIONAL FUSIONS TO OBTAIN A TRANSPOSITION MUTANT" GENE (AMSTERDAM), vol. 63, no. 2, 1988, pages 277-285, XP002152830 ISSN: 0378-1119 the whole document	17
A	ZHOU M ET AL: "TNS TRANSPONASE MUTANT THAT ALTER DNA BINDING SPECIFICITY" JOURNAL OF MOLECULAR BIOLOGY, GB, LONDON, vol. 271, no. 3, 1997, pages 362-373, XP002052643 ISSN: 0022-2836 the whole document	
A	DEVINE S E ET AL: "EFFICIENT INTEGRATION OF ARTIFICIAL TRANSPOSONS INTO PLASMID TARGETS IN VITRO: A USEFUL TOOL FOR DNA MAPPING, SEQUENCING AND GENETIC ANALYSIS" NUCLEIC ACIDS RESEARCH, GB, OXFORD UNIVERSITY PRESS, SURREY, vol. 22, no. 18, 1994, pages 3765-3772, XP002072909 ISSN: 0305-1048 the whole document	
P,X	NAUMANN, T.A. ET AL.: "Trans catalysis in Tn5 transposition." PROC.NAT'L.ACAD.SCI.USA, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 8944-9, XP002152831 the whole document	1-17